EyePoint, Inc. - 8-K Filing
EyePoint announces strategic prioritization to focus on DURAVYU for diabetic macular edema (DME), including a workforce reduction of ~53% and early conclusion of Phase 3 wet AMD trials. (Items: 2.02 Results of Operations and Financial Condition, 2.05 Costs Associated with Exit or Disposal Activities, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $EYPT
Read the full article at SEC EDGAR
Part of the story EyePoint, Inc. - 8-K Filing (2 articles)